GlaxoSmithKline may not be doing so well compared to peers, City says Chief executive Emma Walmsley expressed firm commitment to her plans after the spinoff on Wednesday, which may leave Elliott Management little leeway with its agenda GlaxoSmithKline PLC’s (LON:GSK) pipeline value relative to peers may be weak and its research and development productivity may be poor, City analysts say. The pharma giant scores below average when compared to peers with poor growth and replacement power product concentration, offsetting good pricing power and limited risk around generics, Credit Suisse noted. On Wednesday, the company said healthcare systems and consumer trends will approach normality in the second half of the year.